Cellular Therapies: Revolutionizing Cancer Therapy
Part 3: CTL019 in Relapsed Refractory Pediatric Acute Lymphoblastic Leukemia


Related Videos (117)

In this third of four videos on the topic of cellular therapies for the hematologic malignancies, Carl H June, MD, describes the case of Emily Whitehead, the first pediatric patient treated with CAR T cell therapy for resistant, refractory acute lymphoblastic leukemia (ALL). Emily is now in her fourth year of complete remission. Dr. June also discusses the ELIANA study now ongoing in pediatric patients with relapsed and refractory B-cell ALL.

To view other parts of this program:

Part 1: Adoptive Cell Therapy - An Introduction

Part 2: CTL019 Therapy in Chronic Lymphocytic Leukemia

Part 4: Adoptive Cell Therapy - Lessons Learned, Issues and the Future


Penn PhysicianLink®

Penn PhysicianLink® is an exclusive program that helps all referring physicians connect with Penn Medicine. This comprehensive package of support services expedites and facilitates direct physician communication for patient consults, referrals and transfers.

Learn more about Penn PhysicianLink®